Table 2.

Adjusted associations between sphingolipids and vitamin D₃ supplementation *.

Metabolites.	600 IU/day		2000 IU/day		4000 IU/day
	β (95% CI)	p	β (95% CI)	p	β (95% CI)	p
C16Cer	0.06 (−0.40, 0.53)	0.791	0.09 (−0.36, 0.54)	0.702	0.22 (−0.23, 0.54)	0.336
C18Cer	0.44 (0.00, 0.87)	0.049	0.52 (0.10, 0.94)	0.016	0.58 (0.15, 1.00)	0.008
C16dhCer	−0.06 (−0.57, 0.46)	0.830	−0.22 (−0.71, 0.28)	0.369	−0.00 (−0.51, 0.50)	0.988
C18dhCer	0.28 (−0.33, 0.90)	0.363	0.54 (−0.05, 1.15)	0.071	0.39 (−0.21, 1.00)	0.200
Sphingosine	−0.09 (−0.88, 0.71)	0.833	−0.27 (−1.03, 0.50)	0.499	−0.35 (−1.13, 0.43)	0.382
S1P	−0.17 (−0.86, 0.53)	0.638	0.26 (−0.42, 0.93)	0.460	−0.42 (−1.10, 0.27)	0.232
C16SM	0.21 (−0.19, 0.62)	0.299	0.26 (−0.13, 0.65)	0.198	0.28 (−0.11, 0.68)	0.160
C18SM	0.30 (−0.18, 0.76)	0.222	0.61 (0.15, 1.06)	0.009	0.68 (0.22, 1.15)	0.004

* Mixed-effects models were adjusted for age, sex, and BMI. Levels of metabolites were standardized. Abbreviations: C16Cer, N-palmitoyl-sphingosine (d18:1/16:0); C18Cer, N-stearoyl-sphingosine (d18:1/18:0); C16dhCer, N-palmitoyl-sphinganine (d18:0/16:0); C18dhCer, N-stearoyl-sphinganine (d18:0/18:0); S1P, sphingosine 1-phosphate; C16SM, palmitoyl sphingomyelin (d18:1/16:0); C18SM, stearoyl sphingomyelin (d18:1/18:0).